We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
 ERYtech Pharma Signs an Agreement with M. D. Anderson Cancer Center
News

ERYtech Pharma Signs an Agreement with M. D. Anderson Cancer Center

 ERYtech Pharma Signs an Agreement with M. D. Anderson Cancer Center
News

ERYtech Pharma Signs an Agreement with M. D. Anderson Cancer Center

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of " ERYtech Pharma Signs an Agreement with M. D. Anderson Cancer Center"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ERYtech Pharma, a specialty pharma company located in France and in USA (Philadelphia), announces a collaborative research agreement in the field of personalized medicine focusing on ERYtech’s product, GRASPA®, which consists of red blood cell-encapsulated L-asparaginase (L-ASP).

“Collaboration with M. D. Anderson Cancer Center provides us the opportunity to develop a clinically-compatible biomarker assay and to rationally prescribe GRASPA® to patients who are most likely to respond. Toward that end, the M. D. Anderson’s researchers will analyze patient samples from ERYtech’s clinical trials.”

Pr. John Weinstein, Chair of the Department of Bioinformatics and Computational Biology at M.D. Anderson Cancer Center (Houston, TX) and principal investigator of the project, states “L-ASP is a standard component of leukemia chemotherapy regimens, but it’s not used yet against solid tumors due to erratic activity. We’ve identified a candidate biomarker, asparagine synthetase (ASNS) that may predict L-ASP activity against solid tumors.”

Dr. Philip Lorenzi, who leads the project, adds “We’re very interested in studying GRASPA® because of its reported reduction of L-asparaginase side effects.”

ERYtech Pharma’s Co-Founder and CEO, Dr. Yann Godfrin says “Collaboration with M. D. Anderson Cancer Center provides us the opportunity to develop a clinically-compatible biomarker assay and to rationally prescribe GRASPA® to patients who are most likely to respond. Toward that end, the M. D. Anderson’s researchers will analyze patient samples from ERYtech’s clinical trials.”
Advertisement